Rewriting the Code
of Neurological Disease

Company

About

Vico Therapeutics is a neurology genetic medicine company pioneering targeted treatments for devastating disorders. Our lead program, VO659, an antisense oligonucleotide (ASO) therapy, is designed to strike at the underlying cause of diseases such as Huntington’s disease and spinocerebellar ataxias (SCA), – the CAG repeat expansion mutation – while carefully preserving essential protein function.

This novel approach has the potential to bring new hope to patients and families that have long awaited effective therapies.

Our Story: A Journey of Innovation and Perseverance

Our Approach: Targeting the Genetic Source of Neurodegenerative Diseases

At the heart of Vico’s approach lies a profound commitment to precision. We design our ASO therapies to target the genetic drivers of neurodegenerative diseases, such as the CAG repeat expansion mutation that underlie devastating conditions like Huntington’s disease and various spinocerebellar ataxias.

Our lead program, VO659, exemplifies this targeted strategy. VO659 is capable of addressing nine distinct polyglutamine diseases through a single, innovative molecule - an approach that is distinct from any other ASO therapy. By precisely targeting the genetic roots of these disorders, we aim to unlock transformative treatments that can profoundly improve the lives of those affected by rare neurological diseases.

Scroll to Top
Leadership
Leadership micah mackison

Leadership

Micah Mackison

Chief Executive Officer
Linkedin icon

Mr. Micah Mackison was appointed CEO of Vico Therapeutics in August 2022. Prior to this role, Micah served as Chief Business Officer and Executive Vice President of Strategy and Corporate Development at Locanabio, an RNA-targeted gene therapy company. At Locanabio, he was instrumental in setting strategy, raising capital and helping build an organization focused on genetic neurological diseases. Prior to Locanabio, Micah held several leadership positions in corporate development and strategy. He served as Senior Vice President, Corporate Development and Strategy at Assembly Biosciences where he led business development efforts. Previously, Micah served as Head of Corporate Strategy and Senior Director, New Ventures at H. Lundbeck A/S, where he was focused on neuroscience. Prior to Lundbeck’s acquisition, he was Director, Corporate Development and M&A at Ovation Pharmaceuticals, a neuroscience-focused company that launched the first product for Huntington’s disease.

Earlier in his career, Micah held financial roles at Eli Lilly and Pfizer. He earned a B.S. in Finance from the Kelley School of Business at Indiana University.